KZR
Kezar Life Sciences Inc (KZR)
Healthcare • NASDAQ • $7.29-0.95%
- Symbol
- KZR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $7.29
- Daily Change
- -0.95%
- Market Cap
- $53.86M
- Trailing P/E
- N/A
- Forward P/E
- -1.84
- 52W High
- $7.55
- 52W Low
- $3.53
- Analyst Target
- $6.00
- Dividend Yield
- N/A
- Beta
- 0.41
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Company websiteResearch KZR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.